Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients

Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E (2000) Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 41:1649–1656

Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B (2004) Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10:2584–2586

Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245(1):68–73

Vatavuk Z, Bencic G, Mandic Z (2007) Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol 17:269–271

Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE et al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233–237

Mason JO 3rd, Albert MA Jr, Vail R (2006) Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26:356–357

Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352–354

Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26:354–356

Grisanti S, Bieste S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU (2006) Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142:158–160

Iliev ME, Domingo D, Wolf-Schnurrbursch U, Wolf S, Sarra G (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142:1054–1056

Jonas JB, Spandau UH, Schlichtenbrede F (2007) Intravitreal bevacizumab for filtering surgery. Opthalmic Res 39:121–122

Kahook MY, Schuman JS, Noecker RJ (2006) Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37:144–146

Mason JO 3rd, Albert MA Jr, Mays A, Vail R (2006) Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26:839–841

Silva PJ, Jorge R, Alves CR, Rodrigues ML, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84:556–557

Yazdani S, Hendi K, Pakravan M (2007) Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 16:437–439

Witmer AN, van Blijswijk BC, van Noorden CJ, Vrensen GF, Schlingemann RO (2004) In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem 52:39–52

Iriyama A, Chen YN, Tamaki Y, Yanagi Y (2007) Effect of anti VEGF-antibody on retinal ganglion cells in rats. Br J Opthalmol 91:1230–1233

Bakri SJ, Cameron D, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162–164

Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Opthalmol 143:995–1002

Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC (2001) Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 108:1767–1778

Miki A, Oshima Y, Otori Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Opthalmol 92:1431–1433

Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S (2006) Trabeculectomy with itomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica 220(6):383–388

Elgin U, Berker N, Batman A, Simsek T, Cankaya B (2006) Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma 15(5):466–470

Kiuchi Y, Nakae K, Saito Y, Ito S, Ito N (2006) Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 244(12):1627–1632

Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F et al (2008) Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571–1580

Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G (2008) Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 49(7):3164–3171

Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K (2010) Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmologica 88(1):96–102